Oncotarget

Research Papers:

Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib

Xiaolin Lu _, Weijie Gu, Hailiang Zhang, Yao Zhu, Guohai Shi and Dingwei Ye

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:26879-26887. https://doi.org/10.18632/oncotarget.8568

Metrics: PDF 1357 views  |   HTML 1875 views  |   ?  


Abstract

Xiaolin Lu1,2,*, Weijie Gu1,2,*, Hailiang Zhang1,2, Yao Zhu1,2, Guohai Shi1,2, Dingwei Ye1,2

1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China

2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Guohai Shi, e-mail: [email protected]

Dingwei Ye, e-mail: [email protected]

Keywords: renal cell carcinoma, bone metastasis, oligometastasis, prognosis

Received: December 23, 2015    Accepted: March 10, 2016    Published: April 4, 2016

ABSTRACT

Background: The aim of the study was to investigate whether RCC patients with oligometastatic state of bone metastasis treated with sunitinib had a favorable clinical outcome.

Results: 22 patients were classified into oligometastatic state of bone metastasis with a median OS of 30.1 months (95%CI: 26.3 to 33.8 months). The 45 patients with non-oligometastatic state had a median OS of 12.7 months (95%CI: 9.43 to 16.0 months). Kaplan-Meier analysis showed significant difference between them (Log Rank test p<0.001). When we set patients with only multiple bone (at least 5 sites) metastases as a single group, there was still significant difference between oligometastatic state group and non-oligometastatic state groups. In multivariate Cox proportion hazard ratio analysis, metastatic states (p=0.012), MSKCC score (p=0.002), ECOG (p=0.001) and lymph nodes metastasis (p=0.000) were significantly associated with prognosis. The integration of metastatic state into the MSKCC risk model improved the c-index from 0.651 to 0.752

Method: 67 patients from Fudan University Shanghai Cancer Center with bone metastatic RCC were divided into 2 metastatic states. One included those with oligometastatic state of bone metastasis with less than 5 sites of bone metastasis. The other involved those patients with multiple bone metastases (at least 5 sites) or together with other sites of metastasis. Then patients with only multiple bone (at least 5 sites) metastases were set into a single group.

Conclusion: RCC patients with oligometastatic state of bone metastasis treated with sunitinib had a favorable clinical outcome.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8568